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Although compelling diagnostic definitions and evidence-based treatment 
recommendations for schizoaffective disorder are lacking, clinicians can still 
develop an effective, individualized treatment regimen for patients with this 
condition. The steps necessary to help patients with schizoaffective disorder 
reach and maintain remission are to confirm the diagnosis, evaluate the 
patient’s predictors of outcome, be aware of the available 
pharmacotherapeutic options and prescribe appropriate medications, and 
implement psychotherapy once patients achieve remission. 
Confirm the Diagnosis 
Because schizoaffective disorder encompasses symptoms of mood 
disorders as well as psychosis, clinicians should complete a differential 
diagnosis to rule out bipolar disorder and schizophrenia. Patients may have 
either bipolar or depressive subtypes of schizoaffective disorder, which are 
defined as having predominately manic or depressive symptoms, 
respectively, in addition to psychosis.1 For more information on confirming a 
diagnosis of schizoaffective disorder, see the J Clin Psychlopedia activity 
“Differentially Diagnosing Schizoaffective Disorder.” 
Evaluate the Predictors of Outcome 
After confirming a diagnosis of schizoaffective disorder, clinicians should 
evaluate the patient’s predictors of outcome, which include previous levels of 
functioning, number of prior episodes, nature of psychotic symptoms, and 
extent of cognitive impairment. Initially assessing these features is critical in 
determining an effective, individualized treatment plan and anticipating the 
patient’s course of illness and outcome. 
Previous functioning. Patients with schizoaffective disorder tend to 
have levels of social and occupational functioning that are better than those 
with schizophrenia but worse than those with bipolar disorder.2 Using a 
cluster analysis, Lipkovich et al3 determined that the better the social and 
occupational functioning that patients with schizoaffective disorder have at 
baseline, the more likely they will have good treatment outcomes. 
Number of episodes. As patients experience more episodes of 
schizoaffective disorder, their chances of achieving full recovery dramatically 
decline. For example, Marneros et al4 found that the primary factors in 
persisting psychosocial deficits among patients with schizoaffective disorder 
included having a high number of episodes and a high annual frequency of 
episodes. Further, having a high number of episodes also influenced the 
development of negative social consequences due to the illness. 
 
 
AV 1. Overall Outcomes According to Congruency of Mood Symptoms During 10 Years of Follow-Up 
(00:20)
Nature of psychosis. By definition, patients with schizoaffective disorder 
have psychotic symptoms, but the persistence and presentation of those 
symptoms can predict outcomes for patients. For example, patients with less 
persistent psychotic symptoms have a better prognosis than those with more 
persistent psychosis.4 And, patients with mood-incongruent psychotic 
symptoms, ie, inappropriate to the mood episode, are likely to have poor 
outcomes (AV 1), including poor psychosocial functioning as well as the 
presence of major psychotic symptoms.5 
Cognitive impairment. Because cognitive impairment is closely related 
to functioning, clinicians should evaluate deficits in patients with 
schizoaffective disorder. The premorbid intellectual, language, and behavioral 
functioning of patients with schizoaffective disorder was found to be similar 
to that of schizophrenia patients and worse than that of bipolar disorder 
patients.6 Additionally, one study7 found that neurocognitive performance 
was a better predictor of occupational functioning, ie, employment status and 
the ability to obtain a job, than were the clinical symptoms of schizoaffective 
disorder.  
Implement Pharmacotherapy 
After evaluating each patient’s predictors of outcome, formulate an 
individualized treatment plan based on the available evidence, which is 
categorized below by medication in order of the studies’ methodological 
strength. The amount of data for schizoaffective disorder is limited because 
most trials have examined subsamples of schizoaffective disorder in addition 
to schizophrenia. Very limited data is available for compounds not listed 
below, including conventional antipsychotics, lithium, or valproate. 
 
 AV 2. Mean Total PANSS Scores Over 6 Weeks With Paliperidone ER Vs Placebo (00:21)
Paliperidone. This is the only compound that has been assessed in a 
specifically designed, large, randomized, placebo-controlled study8 for this 
condition. Canuso et al8 examined acute schizoaffective disorder (N = 316) 
and found that the atypical antipsychotic paliperidone ER (12 mg/d) 
significantly improved total scores on the PANSS (AV 2, P = .003), the CGI-S-
SCA (P < .001), the YMRS (for those with prominent manic symptoms, 
P < .001), and the HDRS (for those with prominent depressive symptoms, 
P < .05) compared with placebo. Overall, the medication was well tolerated; 
headache and tremor were the most common adverse events, although 
headache was reported more often in the placebo group. 
Ziprasidone and aripiprazole. Pooled data from 2 double-blind placebo-
controlled trials9 of schizophrenia, focusing on the subset of patients with 
schizoaffective disorder (n = 115) reported significant dose-related 
improvements with ziprasidone (with 160 mg/d having the largest effect) on 
the BPRS total score, BPRS Core Items subscale, BPRS Manic Items, and the 
CGI-S (P < .01 for all) compared with placebo. The most common medication-
induced adverse events were general pain and headache, but a notable lack 
of many adverse events, such as EPS and sexual dysfunction, was apparent. 
 
 AV 3. Mean Change in PANSS Scores Over 4 Weeks With Aripiprazole Vs Placebo (00:20)
Another pooled analysis10 of 2 double-blind placebo-controlled trials of a 
schizoaffective disorder subset of subjects (n = 179) found that aripiprazole 
(up to 30 mg/d) significantly improved total scores on the PANSS (P = .038) 
and the CGI-I (P = .023) compared with placebo (AV 3). Commonly reported 
adverse effects of aripiprazole were headache, agitation, and insomnia, 
although the placebo group reported higher rates for each of these events. 
Topiramate. A small placebo-controlled, double-blind pilot study11 of 
topiramate (mean dose = 276 mg/d) added to mood stabilizers or atypical 
antipsychotics for schizoaffective disorder, bipolar type (N = 48) did not show 
efficacy. Similar reductions in PANSS, YMRS, and CGI-S scores were reported 
for both topiramate and placebo. No serious adverse events were found, 
although the topiramate group experienced significantly more weight loss 
(P < .02) than placebo-treated patients. 
Olanzapine. A comparative double-blind study12 of olanzapine (mean 
dose = 11.5 mg/d) versus haloperidol (mean dose = 10 mg/d) in a 
schizoaffective disorder subset (n = 300) demonstrated significantly greater 
improvements in total scores for the PANSS (P = .003), the BPRS (P = .002), 
and the MADRS (P < .001) with olanzapine. Patients treated with olanzapine 
had significantly less occurrence of all adverse events, except for increased 
appetite, than haloperidol.  
Risperidone. In a double-blind comparative study13 of risperidone (mean 
dose = 5.5 mg/d) and haloperidol (mean dose = 10.8 mg/d), patients with 
schizoaffective disorder (N = 62) had symptomatic improvement with both 
medications on the PANSS, the CARS-M, and the HDRS, but the differences 
were not significant. Risperidone was better tolerated than haloperidol, with 
significantly more haloperidol-treated patients experiencing EPS (P = .03). In 
an open study14 of schizoaffective disorder or bipolar disorder (N = 541), the 
addition of risperidone (mean dose = 3.9 mg/d) to mood stabilizers showed 
significant improvement on the YMRS, the HDRS, the PANSS, and the CGI 
(P < .0001 for all). The adjunctive risperidone was well tolerated, with only 
2.4% of subjects experiencing weight gain, which was the most commonly 
reported adverse event. 
Treatment adherence. To ensure that patients have the opportunity to 
achieve remission, clinicians should educate patients about their illness to 
help them have awareness and insight, address any concerns patients have 
about taking medication, and identify potential safety problems and barriers 
to adherence, such as co-occurring personality or substance use disorders. 
For patients who have difficulty adhering to a daily medication regimen, 
clinicians may consider implementing a long-acting injectable formulation of 
the medication. Additionally, psychotherapy can be used, but should only be 
employed when patients have reached remission. For more information on 
improving treatment adherence, see the J Clin Psychlopedia activity 
“Improving Treatment Adherence in Schizoaffective Disorder.”  
Less 
Add Psychoeducation 
When patients have reached remission, which is the time when they are 
best suited to understand, learn, and develop strategies to cope with the 
illness, psychoeducation can help to improve patient outcomes by increasing 
illness insight and awareness, improving treatment adherence, and helping 
patients and caregivers identify early signs of relapse. Although no studies 
specific to schizoaffective disorder are available, data from bipolar disorder 
and schizophrenia trials may be helpful.  
 
 
AV 4. Rehospitalization Rates at 12 and 24 Months for Patients Who Did and Did Not Receive 
Psychoeducation (00:25)
In studies of schizophrenia, psychoeducation improved patients’ 
knowledge of their illness,15,16 treatment adherence,17 and quality of life15 as 
well as reduced rehospitalization rates for those with 2 to 5 previous 
psychotic episodes (AV 4).17 
In a study18 of bipolar disorder, group psychoeducation reduced the 
number of relapses and recurrences, reduced the number and length of 
hospitalizations, and increased the time to any mood recurrence. 
Additionally, caregiver psychoeducation has been shown to reduce the 
recurrence and increase the time to intervention for any mood episode.19 
Individualize Treatment 
Individualizing treatment for patients with schizoaffective disorder 
requires merging the evidence base from schizoaffective disorder, 
schizophrenia, and bipolar disorder and tailoring treatment plans to each 
patient’s specific schizoaffective subtype, eg, bipolar type or depressive type. 
Bipolar type. Atypical antipsychotics should be given for patients with 
schizoaffective disorder, bipolar type, particularly when psychotic and manic 
symptoms are present. Evidence in bipolar disorder suggests that combining 
an atypical antipsychotic and mood stabilizer is the preferred first-line 
treatment20; both specific medication choices should be guided by individual 
symptom profiles and treatment tolerability. After the patient reaches 
remission, psychoeducation should be instituted and the medication regimen 
that helped the patient achieve remission should be continued through the 
maintenance phase; atypical antipsychotic monotherapy is also acceptable 
during this phase of treatment. 
Depressive type. Evidence for the depressive subtype of schizoaffective 
disorder is so limited that the recommendations here are from clinical 
practice rather than clinical trials. Generally, using an atypical antipsychotic 
plus an antidepressant or a mood stabilizer should be sufficient to manage 
schizoaffective disorder, depressive type, but again, the individual patient’s 
symptomatic profile and tolerability should guide specific medication choices. 
Additionally, psychoeducation should be implemented once the patient 
achieves remission and enters the maintenance phase of treatment. 
For Clinical Use 
 Complete a differential diagnosis of schizoaffective disorder, distinguishing it from 
schizophrenia and bipolar disorder  
 Evaluate each patient’s predictors of outcome, ie, previous levels of functioning, 
number of prior episodes, nature of psychotic symptoms, and extent of cognitive 
impairment  
 Be aware of the pharmacotherapeutic options available for schizoaffective disorder 
and their level of evidence  
 Allow individual patient’s symptomatic profile and tolerability to guide specific 
medication selection  
 Implement psychoeducation after the patient has reached remission  
 
Complete the differential diagnosis training module and then come 
back to complete the posttest. 
Drug Names 
aripiprazole (Abilify), haloperidol (Haldol and others), lithium (Eskalith and 
others), olanzapine (Zyprexa), paliperidone (Invega), risperidone (Risperdal 
and others), topiramate (Topamax and others), ziprasidone (Geodon) 
Abbreviations 
BPRS = Brief Psychiatric Rating Scale, CARS-M = Clinician-Administered 
Rating Scale for Mania, CGI-I/S/SCA = Clinical Global Impressions-
Improvement/Severity/Schizoaffective Disorder scale, EPS = extrapyramidal 
symptoms, ER = extended release, HDRS = Hamilton Depression Rating 
Scale, MADRS = Montgomery-Asberg Depression Rating Scale, PANSS = 
Positive and Negative Syndrome Scale, YMRS = Young Mania Rating Scale 
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